Renflexis (Infliximab-abda) for Psoriasis

Overview
Renflexis is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat active psoriatic arthritis and chronic severe plaque psoriasis in people who are candidates for systemic therapy. Renflexis may be referred to by its drug name, infliximab-abda.

Renflexis is a biosimilar of Remicade. As defined by the FDA, a biosimilar is a biological product that is approved based on a showing that it is highly similar to an already-approved biological product.

Renflexis is a biologic drug. It is a genetically engineered antibody used by the immune system to identify and neutralize substances. Renflexis is believed to work by attaching to tumor necrosis factor alpha (TNF-alpha), a chemical messenger involved in autoimmune attacks. Renflexis binds to TNF-alpha and prevents it from signaling the immune system to attack the connective tissues.

How do I take it?
Renflexis is administered as an intravenous infusion every eight weeks, after initial loading doses.

Renflexis is available in vial form.

Side effects
The FDA-approved label for Renflexis lists common side effects including infections, infusion-related reactions, headache, and abdominal pain.

Rare but serious side effects listed for Renflexis can include blood disorders, severe infections, increased risk for certain types of cancer, heart and liver failure, lupus-like syndrome, and the development of neurological conditions such as multiple sclerosis.

For more details about this treatment, visit:

Renflexis — Organon
www.renflexis.com